The pharmaceutical industry is challenged with complex and far-reaching issues across multiple fronts: declining revenues, increasing cost pressures, and evolving regulatory hurdles, to name just a few. As a result, the old model of large-scale, in-house R&D for drug discovery and development no longer fits. This paper explores how pharmaceutical companies are moving to a blended model that incorporates external partnerships and collaborations to achieve results.
The Shift from Internal to External R&D Partnerships
Strategy and Advisory, Life Sciences